Researchers published results showing in‑vivo base editing corrected a genetic lesion and reversed disease phenotypes in a neurodevelopmental disorder model. The work, reported in Nature Biotechnology, demonstrates therapeutic reversal after systemic or targeted delivery of base‑editing machinery in preclinical studies. Base editing is a precision genome‑editing approach that converts single nucleotides without inducing double‑strand DNA breaks; here investigators used that modality to restore gene function and observe behavioral and molecular recovery in treated animals. The study clarifies delivery strategies, editing windows, and safety readouts critical for translating in‑vivo editing to pediatric indications. While encouraging, the approach will require rigorous safety evaluation—off‑target edits, immune responses to editors, and durable efficacy remain central regulatory and translational questions before clinical steps.